About MoonLake Immunotherapeutics
https://www.moonlaketx.comMoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.
CEO
Jorge Santos da Silva
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 42
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Needham
Buy
Guggenheim
Buy
Goldman Sachs
Buy
Wedbush
Outperform
Wolfe Research
Outperform
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BVF INC/IL
Shares:19.75M
Value:$343.87M
AVORO CAPITAL ADVISORS LLC
Shares:2M
Value:$34.82M
CORMORANT ASSET MANAGEMENT, LP
Shares:1.99M
Value:$34.72M
Summary
Showing Top 3 of 151
About MoonLake Immunotherapeutics
https://www.moonlaketx.comMoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $70.69M ▲ | $-69.73M ▼ | 0% | $-1.1 ▼ | $-66.64M ▼ |
| Q2-2025 | $0 | $59.96M ▲ | $-55.22M ▼ | 0% | $-0.87 ▼ | $-53.18M ▼ |
| Q1-2025 | $0 | $47.48M ▼ | $-39.94M ▲ | 0% | $-0.63 ▲ | $-40.01M ▲ |
| Q4-2024 | $0 | $49.58M ▲ | $-45.6M ▼ | 0% | $-0.72 ▼ | $-48.28M ▼ |
| Q3-2024 | $0 | $43.08M | $-35.39M | 0% | $-0.56 | $-35.99M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $380.48M ▼ | $414.33M ▼ | $123.14M ▲ | $288.91M ▼ |
| Q2-2025 | $425.08M ▼ | $460.1M ▼ | $102.15M ▲ | $353.73M ▼ |
| Q1-2025 | $480.13M ▲ | $511.26M ▲ | $98.68M ▲ | $407.52M ▼ |
| Q4-2024 | $448.03M ▼ | $477.93M ▼ | $24.54M ▲ | $446.83M ▼ |
| Q3-2024 | $493.92M | $518.21M | $22.71M | $488.2M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-70.69M ▼ | $-44.54M ▲ | $88.4M ▲ | $480K ▲ | $44.05M ▲ | $-44.54M ▲ |
| Q2-2025 | $-56.05M ▼ | $-54.53M ▼ | $88.25M ▲ | $0 ▼ | $35.12M ▼ | $-54.53M ▼ |
| Q1-2025 | $-40.56M ▲ | $-38.14M ▲ | $56.25M ▲ | $73.12M ▲ | $91.14M ▲ | $-38.17M ▲ |
| Q4-2024 | $-45.6M ▼ | $-48.47M ▼ | $-147.33M ▼ | $150.71K ▼ | $-195.23M ▼ | $-48.65M ▼ |
| Q3-2024 | $-36.11M | $-25.28M | $58.28M | $183K | $32.87M | $-25.41M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $300.00M ▲ | $300.00M ▲ | $300.00M ▲ |
CEO
Jorge Santos da Silva
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 42
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Needham
Buy
Guggenheim
Buy
Goldman Sachs
Buy
Wedbush
Outperform
Wolfe Research
Outperform
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BVF INC/IL
Shares:19.75M
Value:$343.87M
AVORO CAPITAL ADVISORS LLC
Shares:2M
Value:$34.82M
CORMORANT ASSET MANAGEMENT, LP
Shares:1.99M
Value:$34.72M
Summary
Showing Top 3 of 151